The DOI matches its Crossref record; 59 of the 60 references it cites were found in a registry or an index, and 1 are not checked yet.
Mystical-type experiences occasioned by ketamine mediate its impact on at-risk drinking: Results from a randomized, controlled trial
Abstract
Background: Sub-anesthetic ketamine administration may be helpful for substance use disorders. Converging evidence suggests that the efficacy of ketamine for certain conditions may implicate a subset of its psychoactive effects. Aims: The aim of this analysis is to evaluate whether the mystical-type effects of ketamine are critical for clinical efficacy in alcohol-dependent individuals. In this secondary analysis, we determine if a subset of the psychoactive effects of ketamine, the so-called mystical-type experience, mediates the effect of ketamine, when combined with motivational enhancement therapy, on at-risk drinking behavior in alcohol-dependent individuals interested in treatment. Methods: Forty alcohol dependent adults were randomized to either a 52-minute infusion of ketamine or midazolam, which they received on a designated quit-day during the second week of a five-week motivational enhancement therapy regimen. Psychoactive effects were assessed following the infusion, and alcohol use was monitored for the subsequent 3 weeks at each twice-weekly visit. Results: We found that ketamine leads to significantly greater mystical-type effects (by Hood Mysticism Scale) and dissociation (by Clinician Administered Dissociative States Scale) compared to the active control. Ketamine also led to significant reduction in at-risk drinking. The Hood Mysticism Scale, but not Clinician Administered Dissociative States Scale score, was found to mediate the effect of ketamine on drinking behavior. Conclusions: This trial adds evidence to the literature on the importance of mystical-type experiences in addiction treatment. Future research should continue to investigate the relationship between the psychoactive effects of psychedelic therapeutics and clinical outcomes for other substance use and mental health disorders.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Findings from clinical studies on ketamine for the treatment of addiction support the notion that spiritual (Krupitsky and Grinenko, 1997) or mystical-type experiences (Rothberg et al., 2021;Dakwar et al., 2018) may also mediate its therapeutic effect.”
From Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review (2022) · cites this paper as Rothberg et al., 2021
Citations
Cites
The varieties of religious experience: A study in human nature.
James, W. (1902) · doi:10.1037/10004-000 · Cited by 5,204
Grant, B. F., Stinson, F. S., Dawson, D. A., Chou, S. P., Dufour, M. C., Compton, W., Pickering, R. P., & Kaplan, K. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.8.807 · Cited by 2,889
mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881 · cited 1×
“…and Schatzberg, 2015), possible neural mechanisms include the promotion of neurogenesis, dampened functional connectivity, sustained default-mode network attenuation, and glutamate modulation (Duman et al., 2012; Li et al., 2010; Maeng et al., 2008; Scheidegger et al., 2012; Zanos et al., 2016).”
BackgroundGriffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201 · cited 1×
“…ketamine-occa-sioned mystical-type experience in cocaine-dependent research volunteers engaged in human laboratory studies, as well as on studies investigating psilocybin for end-of-life anxiety and tobacco dependence (Dakwar et al., 2014b, 2018; Garcia-Romeu et al., 2014; Griffiths et al., 2016).”
BackgroundHettema, J., Steele, J., & Miller, W. R. (2005) · Annual Review of Clinical Psychology · doi:10.1146/annurev.clinpsy.1.102803.143833 · Cited by 1,803
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684 · cited 3×
“The mystical-type effects of serotonergic hallucinogens, such as psilocybin, have also been shown to predict a positive response in diverse psychiatric and healthy populations (Garcia-Romeu et al., 2014; Griffiths et al., 2006, 2008; MacLean et al., 2011).”
BackgroundNMDAR inhibition-independent antidepressant actions of ketamine metabolites
Zanos, P., Moaddel, R., Morris, P. J., Georgiou, P., Fischell, J., Elmer, G. I., Alkondon, M., Yuan, P., Pribut, H. J., Singh, N. S., et al. (2016) · Nature · doi:10.1038/nature17998 · Cited by 1,609
Applied Survival Analysis: Regression Modeling of Time‐to‐Event Data
Hosmer, D. W., Lemeshow, S., & May, S. (2008) · Wiley Series in Probability and Statistics · doi:10.1002/9780470258019 · Cited by 1,298
Human hallucinogen research: guidelines for safety
Johnson, M., Richards, W., & Griffiths, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108093587 · Cited by 1,203
2010 National and State Costs of Excessive Alcohol Consumption
Sacks, J. J., Gonzales, K. R., Bouchery, E. E., Tomedi, L. E., & Brewer, R. D. (2015) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2015.05.031 · Cited by 1,180 · cited 1×
“Alcohol misuse is a significant problem in the USA, with severe medical, psychological, and economic consequences to both individuals and society at large (Centers for Disease Control and Prevention, 2013; National Highway Traffic Safety Administration, 2017; Sacks et al., 2015; Substance Abuse and Mental Health Servi…”
Background
Research works printed but not linked: 7
- Borgonovi R, 2014, Aldous Huxley Annual, 12, 72
- Burns L, 2002, J Trauma Stress, 68, 299
- Centers for Disease Control and Prevention (CDC), 2013, Alcohol Related Disease Impact (ARDI) Application
- Escohotado A, 1999, A Brief History of Drugs: From the Stone Age to the Stoned Age, 114
- McHugh RK, 2010, Psychiatr Clin, 33, 511
- National Highway Traffic Safety Administration, 2017, Traffic Safety Facts: Alcohol-Impaired Driving, 1
- Pahnke WN, 1966, Int J Parapsychol, 8, 295
Cited by
Psychedelics, mystical experience, and therapeutic efficacy: a systematic review
Ko, K., Knight, G., Rucker, J. J., & Cleare, A. J. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.917199 · Cited by 306
Psychedelic-Assisted Psychotherapy—A Systematic Review of Associated Psychological Interventions
Cavarra, M., Falzone, A., Ramaekers, J. G., Kuypers, K. P. C., & Mento, C. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.887255 · Cited by 171
Kohtala, S. (2021) · Pharmacological Reports · doi:10.1007/s43440-021-00232-4 · Cited by 167
Schimmers, N., Breeksema, J. J., Smith-Apeldoorn, S. Y., Veraart, J., van den Brink, W., & Schoevers, R. A. (2022) · Psychopharmacology · doi:10.1007/s00213-021-06027-y · Cited by 162
Martinotti, G., Chiappini, S., Pettorruso, M., Mosca, A., Miuli, A., Carlo, F. D., d’Andrea, G., Collevecchio, R., Muzio, I. D., Sensi, S. L., et al. (2021) · Brain Sciences · doi:10.3390/brainsci11070856 · Cited by 125
Metadata
- Authors
- Rothberg, R. L., Azhari, N., Haug, N. A., & Dakwar, E.
- Affiliations
- Palo Alto University (US)
- Columbia University Irving Medical Center (US)
- Corresponding author
- Dakwar, Elias
- ORCID
- Rothberg, Rebecca L
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2020-12-13
- Volume
- 35
- Issue
- 2
- Pages
- 150-158
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W3111975240
- Cited by
- 97
- References
- 59
- Citations by year
- 2026: 13 · 2025: 20 · 2024: 25 · 2023: 12 · 2022: 19 · 2021: 8
- FWCI
- 3.91
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Journal of Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Alcohol Abuse and Alcoholism (AA023010)
- National Institute on Drug Abuse (DA031771)
- New York State Psychiatric Institute
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- ketamine, hazardous drinking, alcoholism, motivational enhancement therapy, dissociation, psychoactive effects, mediation, midazolam, alcoholism treatment
- MeSH terms
- Alcohol Drinking, Dissociative Disorders, Double-Blind Method, Female, Hallucinogens, Humans, Ketamine, Male, Midazolam, Middle Aged, Mysticism, Surveys and Questionnaires, Behavior, Addictive, Treatment Outcome, Substance-Related Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mystical-type experiences occasioned by ketamine mediate its impact on at-risk drinking: Results from a randomized, controlled trial. https://app.cochat.ai/papers/10.1177/0269881120970879
- The paper
- Rothberg, R. L., Azhari, N., Haug, N. A., & Dakwar, E. (2021). Mystical-type experiences occasioned by ketamine mediate its impact on at-risk drinking: Results from a randomized, controlled trial. Journal of Psychopharmacology. https://doi.org/10.1177/0269881120970879
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.